Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities.

TitleInflammatory Mediators in Mood Disorders: Therapeutic Opportunities.
Publication TypeJournal Article
Year of Publication2018
AuteursPfau, ML, Menard, C, Russo, SJ
JournalAnnu Rev Pharmacol Toxicol
Volume58
Pagination411-428
Date Published2018 01 06
ISSN1545-4304
KeywordsAnimals, Brain, Cytokines, Humans, Inflammation, Inflammation Mediators, Mood Disorders
Abstract

Mood disorders such as depression are among the most prevalent psychiatric disorders in the United States, but they are inadequately treated in a substantial proportion of patients. Accordingly, neuropsychiatric research has pivoted from investigation of monoaminergic mechanisms to exploration of novel mediators, including the role of inflammatory processes. Subsets of mood disorder patients exhibit immune-related abnormalities, including elevated levels of proinflammatory cytokines, monocytes, and neutrophils in the peripheral circulation; dysregulation of neuroglia and blood-brain barrier function; and disruption of gut microbiota. The field of psychoneuroimmunology is one of great therapeutic opportunity, yielding experimental therapeutics for mood disorders, such as peripheral cytokine targeting antibodies, microglia and astrocyte targeting therapies, and probiotic treatments for gut dysbiosis, and producing findings that identify therapeutic targets for future development.

DOI10.1146/annurev-pharmtox-010617-052823
Alternate JournalAnnu. Rev. Pharmacol. Toxicol.
PubMed ID28992428
PubMed Central IDPMC5826556
Grant ListP50 AT008661 / AT / NCCIH NIH HHS / United States
R01 MH090264 / MH / NIMH NIH HHS / United States
R01 MH104559 / MH / NIMH NIH HHS / United States
T32 MH087004 / MH / NIMH NIH HHS / United States